Rachel L Winer1, John Lin1, Troy D Querec2, Elizabeth R Unger2, Joshua E Stern3, Jessica M Rudd4, Matthew R Golden5, Fred Swanson6, Lauri E Markowitz4, Elissa Meites4. 1. Department of Epidemiology, University of Washington, Seattle, Washington, USA. 2. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. Department of Global Health, University of Washington, Seattle, Washington, USA. 4. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 5. Center for AIDS & STD, University of Washington, Seattle, Washington, USA. 6. Gay City Health Project, Seattle, Washington, USA.
Abstract
BACKGROUND: In the United States, human papillomavirus (HPV) vaccination has been recommended since 2011 for boys aged 11-12 years, with catch-up vaccination recommended through age 26 years for previously unvaccinated men who have sex with men (MSM). METHODS: During 2016-2018, a cross-sectional study enrolled MSM and transgender women aged 18-26 years in Seattle, Washington. Participants submitted self-collected penile swab specimens for HPV genotyping. HPV vaccination history was self-reported. We compared HPV prevalence among vaccinated participants with that in participants with no or unknown vaccination history, using log-binomial regression to estimate adjusted prevalence ratios and confidence intervals. RESULTS: Among 687 participants, 348 (50.7%) self-reported ever receiving ≥1 HPV vaccine dose; the median age at first HPV vaccination was 21 years, and the median age at first sex, 17 years. Overall, the prevalence of penile quadrivalent HPV vaccine (4vHPV)-type HPV was similar in vaccinated participants (12.1%) and participants with no or unknown vaccination (15.6%) (adjusted prevalence ratio, 0.69 [95% confidence interval, .47-1.01]). However, the prevalence was significantly lower in participants vaccinated at age ≤18 years than in those with no of unknown vaccination (0.15 [.04-.62]), corresponding to a vaccine effectiveness of 85% against 4vHPV-type HPV. CONCLUSIONS: Results suggest that HPV vaccination is effective in preventing penile HPV infections in young MSM when administered at age ≤18 years.
BACKGROUND: In the United States, human papillomavirus (HPV) vaccination has been recommended since 2011 for boys aged 11-12 years, with catch-up vaccination recommended through age 26 years for previously unvaccinated men who have sex with men (MSM). METHODS: During 2016-2018, a cross-sectional study enrolled MSM and transgender women aged 18-26 years in Seattle, Washington. Participants submitted self-collected penile swab specimens for HPV genotyping. HPV vaccination history was self-reported. We compared HPV prevalence among vaccinated participants with that in participants with no or unknown vaccination history, using log-binomial regression to estimate adjusted prevalence ratios and confidence intervals. RESULTS: Among 687 participants, 348 (50.7%) self-reported ever receiving ≥1 HPV vaccine dose; the median age at first HPV vaccination was 21 years, and the median age at first sex, 17 years. Overall, the prevalence of penile quadrivalent HPV vaccine (4vHPV)-type HPV was similar in vaccinated participants (12.1%) and participants with no or unknown vaccination (15.6%) (adjusted prevalence ratio, 0.69 [95% confidence interval, .47-1.01]). However, the prevalence was significantly lower in participants vaccinated at age ≤18 years than in those with no of unknown vaccination (0.15 [.04-.62]), corresponding to a vaccine effectiveness of 85% against 4vHPV-type HPV. CONCLUSIONS: Results suggest that HPV vaccination is effective in preventing penile HPV infections in young MSM when administered at age ≤18 years.
Authors: Dorothy A Machalek; Mary Poynten; Fengyi Jin; Christopher K Fairley; Annabelle Farnsworth; Suzanne M Garland; Richard J Hillman; Kathy Petoumenos; Jennifer Roberts; Sepehr N Tabrizi; David J Templeton; Andrew E Grulich Journal: Lancet Oncol Date: 2012-03-23 Impact factor: 41.316
Authors: Stephen Goldstone; Joel M Palefsky; Anna R Giuliano; Edson D Moreira; Carlos Aranda; Heiko Jessen; Richard J Hillman; Daron G Ferris; Francois Coutlee; Kai-Li Liaw; J Brooke Marshall; Xuehong Zhang; Scott Vuocolo; Eliav Barr; Richard M Haupt; Dalya Guris; Elizabeth I O Garner Journal: J Infect Dis Date: 2011-01-01 Impact factor: 5.226
Authors: Alan G Nyitray; Roberto J Carvalho da Silva; Maria Luiza Baggio; Beibei Lu; Danélle Smith; Martha Abrahamsen; Mary Papenfuss; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano Journal: J Infect Dis Date: 2011-01-01 Impact factor: 5.226
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Harrell W Chesson; C Robinette Curtis; Julianne Gee; Joseph A Bocchini; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2014-08-29
Authors: Petra J Woestenberg; Birgit H B van Benthem; Johannes A Bogaards; Audrey J King; Fiona R M van der Klis; Hella Pasmans; Suzan Leussink; Marianne A B van der Sande; Christian J P A Hoebe Journal: Vaccine Date: 2020-03-19 Impact factor: 3.641
Authors: Raiza Amiling; Rachel L Winer; Michael E Newcomb; Pamina M Gorbach; John Lin; Richard A Crosby; Brian Mustanski; Lauri E Markowitz; Elissa Meites Journal: Hum Vaccin Immunother Date: 2021-12-02 Impact factor: 4.526